288 related articles for article (PubMed ID: 32301699)
1. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2018 Jun; 77(5):421-428. PubMed ID: 28324148
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee YH; Song GG
Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
16. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2017 Aug; 76(6):528-534. PubMed ID: 27312466
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
19. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
Lee YH; Song GG
Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Feb; 82(1):64-70. PubMed ID: 33999266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]